ADOPTION AND PERCEPTION OF GENETIC MAPPING IN BREAST CANCER: A PRELIMINARY AND EXPLORATORY SURVEY AMONG SPECIALISTS IN GOIÁS
DOI:
https://doi.org/10.66104/qhx4xy11Palavras-chave:
Câncer de Mama, Genes BRCA1, Genes BRCA2, Testes GenéticosResumo
Breast cancer is a neoplasm with a significant public health impact, with a proportion of cases associated with hereditary factors, mainly mutations in the BRCA1 and BRCA2 genes. The state of Goiás became a pioneer in Brazil by establishing, through Law No. 20,707/2020, free access to genetic testing for these mutations within the Brazilian Unified Health System (SUS). This study investigates the integration of genetic mapping from the perspective of local specialist physicians. An observational, cross-sectional study was conducted with a convenience sample of 16 physicians (oncologists, breast specialists, and geneticists) practicing in Goiás. A structured electronic questionnaire was used to assess knowledge, frequency of use, and perceived barriers related to genetic mapping. Data were analyzed using descriptive statistics. Most participants (93.8%) reported being aware of genetic mapping, but only 50% used it frequently. The main clinical criteria for ordering the test were diagnosis before the age of 40, direct family history, and triple-negative tumor before the age of 50. The most frequently cited barriers to not using the test were the perception of low usefulness (31.3%) and gaps in genetic counseling. The results point to a discrepancy between theoretical knowledge about testing and its practical application in clinical routine. Attitudinal and operational barriers, such as unfamiliarity with genetic counseling, appear to limit the effective incorporation of this tool, even when it is legally available. It is concluded that the effective implementation of genetic mapping for breast cancer in Goiás depends not only on access to the test, but also on overcoming practical barriers through professional training and the structuring of genetic counseling workflows.
Downloads
Referências
AHMED, Z. Precision medicine with multi-omics strategies, deep phenotyping, and predictive analysis. Progress in Molecular Biology and Translational Science, v. 190, n. 1, p. 101–125, 1 jan. 2022. DOI: https://doi.org/10.1016/bs.pmbts.2022.02.002
ALMOMANI, B. A. et al. The difference in knowledge and concerns between healthcare professionals and patients about genetic-related issues: a questionnaire-based study. PLOS ONE, v. 15, n. 6, p. e0235001, 19 jun. 2020. DOI: https://doi.org/10.1371/journal.pone.0235001
ASSAD, H. et al. Uptake of screening and risk-reducing recommendations among women with hereditary breast and ovarian cancer syndrome due to pathogenic BRCA1/2 variants evaluated at a large urban comprehensive cancer center. Breast Cancer Research and Treatment, v. 206, n. 2, p. 261–272, 12 abr. 2024. DOI: https://doi.org/10.1007/s10549-024-07283-0
BAGWELL, A. K. et al. Outcomes of large panel genetic evaluation of breast cancer patients in a community-based cancer institute. American Journal of Surgery, v. 221, n. 6, p. 1159–1163, jun. 2021. DOI: https://doi.org/10.1016/j.amjsurg.2021.03.060
BILENDUKE, E. et al. A practical method for integrating community priorities in planning and implementing cancer control programs. Cancer Causes & Control, v. 34, supl. 1, p. 113–123, 18 abr. 2023. DOI: https://doi.org/10.1007/s10552-023-01688-w
BRASIL. Ministério da Saúde. Câncer de mama. Disponível em: https://www.gov.br/saude/pt-br/assuntos/saude-de-a-a-z/c/cancer-de-mama.
BRASIL. Ministério da Saúde. Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA). Diretrizes para a detecção precoce do câncer de mama no Brasil. Rio de Janeiro: Ministério da Saúde, 2015.
BRASIL. Ministério da Saúde. Instituto Nacional de Câncer (INCA). Cartilha câncer de mama. 7. ed. Rio de Janeiro: INCA, 2022. Disponível em: https://www.inca.gov.br/sites/ufu.sti.inca.local/files//media/document//cartilha_cancer_de_mama_2022_visualizacao.pdf
CÂNCER - OPAS/OMS. Organização Pan-Americana da Saúde. Disponível em: https://www.paho.org/pt/topicos/cancer.
CÂNCER de mama agora forma mais comum de câncer: OMS tomando medidas. Disponível em: https://www.who.int/pt/news/item/03-02-2021-breast-cancer-now-most-common-form-of-cancer-who-taking-action.
CARVALHO, Versanna. Goiás e UFG oferecem teste genético em câncer de mama herdado. Disponível em: https://ufg.br/n/175465-goias-e-ufg-oferecem-teste-genetico-em-cancer-de-mama-herdado.
CHEHADE, C. H. et al. Trends and disparities in next-generation sequencing in metastatic prostate and urothelial cancers. JAMA Network Open, v. 7, n. 7, p. e2423186, 18 jul. 2024. DOI: https://doi.org/10.1001/jamanetworkopen.2024.23186
CONNER, S. et al. Primary care provider practices, attitudes, and confidence with hereditary cancer risk assessment and testing: a mixed methods study. Genetics in Medicine, v. 27, n. 4, p. 101307, 1 out. 2024. DOI: https://doi.org/10.1016/j.gim.2024.101307
CRISCITIELLO, C.; CORTI, C. Breast cancer genetics: diagnostics and treatment. Genes, v. 13, n. 9, p. 1593, 2022. DOI: https://doi.org/10.3390/genes13091593
GOLD, J. I. et al. Racial and socioeconomic disparities in genetic evaluation and testing in the adult patient population. The American Journal of Human Genetics, v. 113, n. 1, p. 29–40, jan. 2026. DOI: https://doi.org/10.1016/j.ajhg.2025.11.010
GOIÁS. Lei n. 20.707, de 14 de janeiro de 2020. Dispõe sobre a realização do exame de detecção de mutação genética que especifica.
HERZOG, J. S. et al. Genetic epidemiology of BRCA1- and BRCA2-associated cancer across Latin America. npj Breast Cancer, v. 7, n. 1, p. 1–8, 19 ago. 2021. DOI: https://doi.org/10.1038/s41523-021-00317-6
INTERNATIONAL AGENCY FOR RESEARCH ON CANCER (IARC). Global cancer observatory. Disponível em: https://gco.iarc.who.int/en.
KHOURY, M. J. et al. Health equity in the implementation of genomics and precision medicine: a public health imperative. Genetics in Medicine, v. 24, n. 8, abr. 2022. DOI: https://doi.org/10.1016/j.gim.2022.04.009
LASTA, J. L.; GROTO, A. D.; PAULA, A. Assessment of medical knowledge toward genetic testing for individuals with hereditary breast and ovarian cancer syndrome in Brazil. Preventive Medicine Reports, v. 35, p. 102356, 2 ago. 2023. DOI: https://doi.org/10.1016/j.pmedr.2023.102356
LI, S. et al. Cancer risks associated with BRCA1 and BRCA2 pathogenic variants. Journal of Clinical Oncology, v. 40, n. 14, 25 jan. 2022.
MATALON, D. R. et al. Clinical, technical, and environmental biases influencing equitable access to clinical genetics/genomics testing: a points to consider statement of the American College of Medical Genetics and Genomics (ACMG). Genetics in Medicine, v. 25, n. 6, p. 100812, jun. 2023. DOI: https://doi.org/10.1016/j.gim.2023.100812
MOMOZAWA, Y. et al. Expansion of cancer risk profile for BRCA1 and BRCA2 pathogenic variants. JAMA Oncology, v. 8, n. 6, p. 871, 1 jun. 2022. DOI: https://doi.org/10.1001/jamaoncol.2022.0476
NATIONAL COMPREHENSIVE CANCER NETWORK (NCCN). Guidelines for patients details. Disponível em: https://www.nccn.org/patientresources/patient-resources/guidelines-for-patients/guidelines-for-patients-details?patientGuidelineId=77.
NEVES, N. M. B. C. et al. Implicações éticas dos testes genéticos de suscetibilidade ao câncer de mama. Revista Bioética, v. 30, n. 3, p. 636–643, set. 2022. DOI: https://doi.org/10.1590/1983-80422022303557en
NISSELLE, A. et al. Measuring physician practice, preparedness and preferences for genomic medicine: a national survey. BMJ Open, v. 11, n. 7, p. e044408, 1 jul. 2021. DOI: https://doi.org/10.1136/bmjopen-2020-044408
PILARSKI, R. How have multigene panels changed the clinical practice of genetic counseling and testing. Journal of the National Comprehensive Cancer Network, v. 19, n. 1, p. 103–108, 6 jan. 2021. DOI: https://doi.org/10.6004/jnccn.2020.7674
REDE NACIONAL DE CÂNCER FAMILIAL. Disponível em: https://www.inca.gov.br/publicacoes/manuais/rede-nacional-de-cancer-familial.
SCHAIBLEY, V. M. et al. Limited genomics training among physicians remains a barrier to genomics-based implementation of precision medicine. Frontiers in Medicine, v. 9, 18 mar. 2022. DOI: https://doi.org/10.3389/fmed.2022.757212
VAN, S. C. et al. Disparities in OncotypeDx testing and subsequent chemotherapy receipt by geography and socioeconomic status. Cancer Epidemiology, Biomarkers & Prevention, v. 33, n. 5, 25 jan. 2024. DOI: https://doi.org/10.1158/1055-9965.EPI-23-1201
WANG, R.; WANG, Z. Precision medicine: disease subtyping and tailored treatment. Cancers, v. 15, n. 15, p. 3837, 28 jul. 20 DOI: https://doi.org/10.3390/cancers15153837
Downloads
Publicado
Edição
Seção
Licença
Copyright (c) 2026 Pedro Henrique Paulino Pereira de Souza, Isadora Alves Gamboa, Amanda Vitoria de Oliveira Lima, João Victor Martins Bordigoni, Ysabelle de Oliveira Saraiva , Aline de Araújo Freitas, Alisson Martins de Oliveira, Jalsi Tacon Arruda
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
Autores que publicam nesta revista concordam com os seguintes termos:
- Autores mantém os direitos autorais e concedem à revista o direito de primeira publicação, com o trabalho simultaneamente licenciado sob a Licença Creative Commons Attribution que permite o compartilhamento do trabalho com reconhecimento da autoria e publicação inicial nesta revista;
- Autores têm autorização para assumir contratos adicionais separadamente, para distribuição não-exclusiva da versão do trabalho publicada nesta revista (ex.: publicar em repositório institucional ou como capítulo de livro), com reconhecimento de autoria e publicação inicial nesta revista, desde que adpatado ao template do repositório em questão;
- Autores têm permissão e são estimulados a publicar e distribuir seu trabalho online (ex.: em repositórios institucionais ou na sua página pessoal) a qualquer ponto antes ou durante o processo editorial, já que isso pode gerar alterações produtivas, bem como aumentar o impacto e a citação do trabalho publicado (Veja O Efeito do Acesso Livre).
- Os autores são responsáveis por inserir corretamente seus dados, incluindo nome, palavras-chave, resumos e demais informações, definindo assim a forma como desejam ser citados. Dessa forma, o corpo editorial da revista não se responsabiliza por eventuais erros ou inconsistências nesses registros.
POLÍTICA DE PRIVACIDADE
Os nomes e endereços informados nesta revista serão usados exclusivamente para os serviços prestados por esta publicação, não sendo disponibilizados para outras finalidades ou a terceiros.
Obs: todo o conteúdo do trabalho é de responsabilidade do autor e orientador.
